- ADHD medicines shortages – information to support primary care October 2023
- Agomelatine for depression - primary care factsheet - March 2023
- Allergic Rhinitis treatment pathway - June 2019
- Anal Fissure treatment pathway - May 2018
- Antidepressant in Pregnancy Guidance - August 2022
- Antidepressant in Pregnancy Poster - August 2022
- Asthma (adults) - CESEL Guide with treatment pathway
- Asthma Guidelines (Withdrawn) – October 2023
- Atopic dermatitis - Dupilumab outcomes framework - July 2021
- Atopic Dermatitis treatment pathway FINAL July 2023
- Care Homes - safe use of PRN medicines guidance - June 2022
- Care Homes – Anticoagulant best practice guidance - April 2023
- Chronic Pain in Adults (Non-Cancer) - management - March 2019
- Constipation (chronic) guideline - April 2021
- COPD guideline - December 2020
- COVID-19 - NICE and SPS Clinical guidance
- COVID-19 treatments – outcomes and monitoring framework – October 2023
- Delmosmart for methylphenidate MR switch leaflet FINAL
- Dermatology - clobetasol propionate - Specials fact sheet - December 2017
- Dermatology - Lactic acid in Diprobase cream- Specials fact sheet - December 2017
- Dermatology - Monobenzone in cetomacrogol - Specials fact sheet - December 2017
- Dermatology - Primary Care Guidelines – October 2022
- Dermatology- Beclometasone diproprionate - Specials fact sheet - December 2017
- Emollient Guideline FINAL – May 2023
- Emollients patient information leaflet - May 2023
- Epilepsy (Adult Focal) treatment pathway - Oct 2020
- Erectile dysfunction - treatment guidance - December 2020
- Gastroparesis (Adults) - treatment pathway - October 2020
- Glaucoma - Ocular Hypertension- treatment pathway - January 2018
- Gout – primary care management guideline - January 2022
- HPV vaccine anogenital warts - guidance - December 2021
- Hyperhidrosis pathway – June 2023
- Hypersalivation - management options - September 2019
- IBD - dose escalated anti-TNF therapy (Crohn’s Disease) October 2023
- IBD - dual biologic therapy (Crohn’s Disease) – October 2023
- IBD - Pathway Monitoring Framework – 2023
- IBD - treatment pathways with Fe deficiency pathway – October 2023
- Immune Thrombocytopenia (ITP) adult - treatment Pathway - July 2020
- Inhalers - Environmental Impact - Patient Information December 2021
- Inhalers - Environmental Impact - Position Statement - December 2021
- Intravitreal - treatment pathway - April 2018
- Irritable Bowel Syndrome (adults) - treatment Pathway - July 2020
- Jorveza for eosinophilic oesophagitis - GP information leaflet - March 2023
- Lidocaine Plasters - Deprescribing Guide - June 2022
- Menopause - Testosterone gel or sachets leaflet - June 2019
- Neuropathic pain - refractory (Adults) - AED meds info - July 2020
- Neuropathic Pain (Adults) - guidance - June 2022
- Nystatin for early voice prosthesis failure - GP information leaflet
- Oral medicine treatments (off label) guide - January 2019
- Overactive bladder (OAB) - (Adults) - treatment pathway - February 2020
- Papulopustular Rosacea - treatment pathway - March 2019
- Parkinson's Disease - Motor Symptoms Management - July 2018
- Pseudomonas guideline - Non - CF Bronchiectasis - November 21
- Psoriasis - Biologic Treatment Pathway (Adults) - January 2022
- Psoriasis - Pathway Outcomes Monitoring Framework - January 2022
- Reconciling hospital only medicines in primary care - October 2020
- Respimat Reusable Inhaler Factsheet - December 2021
- Restless Legs Syndrome - GP Fact Sheet - May 2017
- Restless Legs Syndrome - Patient leaflets
- Restless Legs Syndrome - Treatment Pathway - February 2020
- Rheumatoid arthritis treatment pathway – September 2023
- Rheumatology Monitoring Framework – September 2023
- Seronegative spondyloarthropathy treatment pathway – September 2023
- Sleep - Cataplexy with narcolepsy pathway - March 2023
- Sleep - GP information on Sleep Hygiene
- Sleep - Non-REM Medicines Information - March 2023
- Sleep - Co-morbid insomnia pathway - March 2023
- Sleep - Narcolepsy GP Factsheet - August 2018
- Sleep - Narcolepsy pathway - August 2018
- Sleep - Non-REM parasomnia pathway – March 2023
- Sleep - Non-REM parasomnias GP and Community Pharmacy fact sheet - March 2023
- Sleep - RBD behaviour GP and Community Pharmacy fact sheet - March 2023
- Sleep - RBD medicines information - March 2023
- Sleep - REM Behaviour Disorder pathway - March 2023
- Steroid Safety – Adrenal Insufficiency Patient Information Leaflet February 2023
- Steroid Safety – Steroid Emergency Card Guidance for Primary Care February 2023
- STOMP and STAMP Guidance - July 2020
- Urticaria - Treatment Pathway - December 2018
- Uterine fibroids - Ulipristal Acetate (Esyma) interim statement - February 2018
- Valproate - GP actions flyer - September 2018
- Vitamin D - (ADULTS) guideline – October 2023
- Xenidate - methylphenidate MR switch leaflet - August 2020
SEL IMOC homeAdult guidelines and pathwaysAnnual reports and work plansCardiovascular disease guidanceCommittee governanceCommittee minutesDiabetes guidanceFormulary recommendations and position statementsLow priority products (NHS England)Paediatric guidelines and pathwaysPoliciesRed, Amber, Green, Grey (RAGG) list definitionsRegional Medicines Optimisation Committee (RMOC) guidanceSelf care (over the counter medicines)Shared care agreements and templatesSupporting information for primary care for significant medicines shortagesTemplate letters
